m+Medelevator.RU
← Поиск публикаций
Journal of Alzheimer's disease : JAD · 2021

Retinal Amyloid Imaging for Screening Alzheimer's Disease.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Tadokoro Koh, Yamashita Toru, Kimura Shuhei, Nomura Emi, Ohta Yasuyuki, Omote Yoshio, Takemoto Mami, Hishikawa Nozomi, Morihara Ryuta, Morizane Yuki, Abe Koji

Аннотация

BACKGROUND: Cost-effective and noninvasive methods for in vivo imaging of amyloid deposition are needed to screen Alzheimer's disease (AD). Although retinal amyloid is a possible diagnostic marker of AD, there are very few studies on in vivo retinal amyloid imaging.

OBJECTIVE: To examine the usefulness of in vivo imaging of retinal amyloid in AD patients.

METHODS: To examine amyloid deposition, 30 Japanese subjects (10 normal control (NC), 7 with mild cognitive impairment (MCI), and 13 with AD) underwent a complete ophthalmic examination, including fundus imaging by scanning laser ophthalmoscopy before and after oral curcumin intake.

RESULTS: Retinal amyloid deposition was greater in AD than in NC subjects (*p < 0.05) while MCI showed a slight but insignificant increase of retinal amyloid deposition relative to NC subjects. Retinal amyloid deposition was correlated with whole gray matter atrophy (r = 0.51, *p < 0.05) but not with the cognitive score of the Mini-Mental State Examination, nor with medial temporal lobe atrophy.

CONCLUSION: The present noninvasive in vivo detection of retinal amyloid deposition is useful for screening AD patients.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты